| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/13/2013 | WO2013085017A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | WO2013085016A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | WO2013084532A1 Prophylactic or therapeutic agent for dysuria |
| 06/13/2013 | WO2013084250A1 Combination of cyclophosphamide and dendritic cells for use in the treatment of uterine cervix carcinoma |
| 06/13/2013 | WO2013084138A1 Cyclic urea derivatives as androgen receptor antagonists |
| 06/13/2013 | WO2013083817A1 Uses of immunoconjugates targeting cd138 |
| 06/13/2013 | WO2013083058A1 Platinum type compound with leaving group being hydroxy acid derivative containing amino group or alkyl amino, and preparation method and use thereof |
| 06/13/2013 | WO2013082875A1 Arsenic compound solution and albumin nanoparticle and lyophilized preparation entrapping arsenic compound prepared using same |
| 06/13/2013 | WO2013082839A1 Drug-loaded liposome for overcoming tumor drug resistance, method for preparing same, and application thereof |
| 06/13/2013 | WO2013082656A1 Cage amine ligands for metallo-radiopharmaceuticals |
| 06/13/2013 | WO2013063679A8 Use of neu1 sialidase inhibitors in the treatment of cancer |
| 06/13/2013 | WO2013058613A3 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient |
| 06/13/2013 | WO2013056684A3 Thiazole derivative as dhodh inhibitor and use thereof |
| 06/13/2013 | WO2013054204A3 A process for making an intermediate of cabazitaxel |
| 06/13/2013 | WO2013054147A3 Erlotinib salts |
| 06/13/2013 | WO2013048169A3 Method for preparing taxane derivatives |
| 06/13/2013 | WO2013045707A3 Biological materials related to c-met |
| 06/13/2013 | WO2013030569A3 Cell- penetrating peptides having a central hydrophobic domain |
| 06/13/2013 | WO2013025064A3 Anti-cancer composition comprising wnt decoy receptors |
| 06/13/2013 | WO2013022257A3 Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
| 06/13/2013 | WO2013020024A3 Maleimide compounds and methods of treatment |
| 06/13/2013 | WO2013015657A3 Novel compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same |
| 06/13/2013 | WO2013009910A3 Eosinophil peroxidase compositions and methods of their use |
| 06/13/2013 | WO2012170664A3 Methods of cancer treatment and prevention through the modulation of sirt4 activity |
| 06/13/2013 | WO2012170573A3 New taccalonolide microtubule stabilizers |
| 06/13/2013 | WO2012162565A3 Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
| 06/13/2013 | WO2012159085A3 Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells |
| 06/13/2013 | WO2012031196A9 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer |
| 06/13/2013 | US20130150649 Sensitization of tumor cells to radiation therapy through administration of endothelin agonists |
| 06/13/2013 | US20130150311 Mixed poloxamer excipients |
| 06/13/2013 | US20130150296 Albumin fusion proteins |
| 06/13/2013 | US20130150287 RECOMBINANT PROTEIN FOR INTRACELLULAR DELIVERY OF siRNA AND COMPOSITION COMPRISING THE SAME |
| 06/13/2013 | US20130149392 Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds |
| 06/13/2013 | US20130149299 Dosages for treatment with anti-egfr antibodies |
| 06/13/2013 | CA2858601A1 Reduction of galectin-3 levels by plasmapheresis |
| 06/13/2013 | CA2858382A1 Mirnas useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods |
| 06/13/2013 | CA2858379A1 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants |
| 06/13/2013 | CA2858164A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | CA2858133A1 Uses of immunoconjugates targeting cd138 |
| 06/13/2013 | CA2858115A1 Artificial antigen presenting cells having a defined and dynamic shape |
| 06/13/2013 | CA2858012A1 Antibodies for epidermal growth factor receptor 3 (her3) |
| 06/13/2013 | CA2857721A1 Pdgf receptor beta binding polypeptides |
| 06/13/2013 | CA2857601A1 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| 06/13/2013 | CA2856364A1 Vectors harboring toxic genes, methods and uses therefor |
| 06/12/2013 | EP2602618A1 Method for screening chronic inflammation suppression agent or cancer metastasis suppression agent having inhibition of bonding of emmprin and s100a9 as indicator |
| 06/12/2013 | EP2601962A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
| 06/12/2013 | EP2601961A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
| 06/12/2013 | EP2601954A1 Therapeutic agent for disease |
| 06/12/2013 | EP2601946A1 Treatment and prevention of diseases related to oxidative stress |
| 06/12/2013 | EP2601202A1 Bone-targeting bisphosphonate duplex drugs |
| 06/12/2013 | EP2601198A1 Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
| 06/12/2013 | EP2601191A2 Compounds and compositions for mitigating tissue damage and lethality |
| 06/12/2013 | EP2601186A2 4-(1h-indol-3-yl)-pyrimidines as alk inhibitors |
| 06/12/2013 | EP2601185A1 Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| 06/12/2013 | EP2601183A1 Coumarin-chalcones as anticancer agents |
| 06/12/2013 | EP2601177A1 N-acylsulfonamide apoptosis promoters |
| 06/12/2013 | EP2600896A2 Treating breast cancer with anti-il-19 antibody |
| 06/12/2013 | EP2600886A1 Use of a peptide enhancing the ability of radiation therapy to kill cancer cells |
| 06/12/2013 | EP2600874A1 Pyrimidine compounds that inhibit anaplastic lymphoma kinase |
| 06/12/2013 | EP2600866A1 Processes for preparing tubulysins |
| 06/12/2013 | EP2600865A1 Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound |
| 06/12/2013 | EP2600860A1 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins |
| 06/12/2013 | EP2600856A1 Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer |
| 06/12/2013 | EP2600844A2 Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof |
| 06/12/2013 | EP2178869B1 Indole compounds as an inhibitor of cellular necrosis |
| 06/12/2013 | CN1942588B Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 06/12/2013 | CN1917922B Use of substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis |
| 06/12/2013 | CN1525857B Method for regulation of gene expression in eukaryotic cells using nordihydroguaiaretic acid derivatives |
| 06/12/2013 | CN1461310B ANtibodies that bind human interleukin-18 and methods of making and using |
| 06/12/2013 | CN103154034A Antibodies that bind human cd27 and uses thereof |
| 06/12/2013 | CN103154003A Free crystal of tricyclic pyrazolopyrimidine derivative |
| 06/12/2013 | CN103153997A Quinazoline derivatives |
| 06/12/2013 | CN103153983A Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1H - indazol - 3 - yl) vinyl) -1 H- pyrazol- 1 -yl) ethanol and its use as FGFR inhibitor |
| 06/12/2013 | CN103153982A 4-(1H-Indol-3-yl) -pyrimidines as ALK inhibitors |
| 06/12/2013 | CN103153980A Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| 06/12/2013 | CN103153975A Novel anphthoquinones for disease therapies? |
| 06/12/2013 | CN103153970A Oxazole And Thiazole Compounds As Ksp Inhibitors |
| 06/12/2013 | CN103153965A Quinoxaline derivates |
| 06/12/2013 | CN103153959A 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators |
| 06/12/2013 | CN103153954A N-acylsulfonamide apoptosis promoters |
| 06/12/2013 | CN103153951A Pyrrolidinones as MetAP-2 inhibitors |
| 06/12/2013 | CN103153345A Amatoxin-conjugates with improved linkers |
| 06/12/2013 | CN103153340A Treatment for neoplastic diseases |
| 06/12/2013 | CN103153339A Monoclonal antibodies against her2 epitope |
| 06/12/2013 | CN103153338A Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
| 06/12/2013 | CN103153332A Compositions and methods for treatment of hematological malignancies |
| 06/12/2013 | CN103153328A Peptide for use in the treatment of breast cancer and/or bone metastases |
| 06/12/2013 | CN103153317A Immunity inducer |
| 06/12/2013 | CN103153311A The use of inhibitors of bruton's tyrosine kinase (btk) |
| 06/12/2013 | CN103153309A Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone |
| 06/12/2013 | CN103153306A Solid dispersion comprising triazole compound |
| 06/12/2013 | CN103153305A Pharmaceutical combinations |
| 06/12/2013 | CN103153303A Combination therapy using a ruthenium complex |
| 06/12/2013 | CN103153302A Biomarkers for mdm2 inhibitors for use in treating disease |
| 06/12/2013 | CN103153292A Combination anti-cancer therapy |
| 06/12/2013 | CN103153290A Antimicrobial formulations that aid in wound healing |
| 06/12/2013 | CN103146703A siRNA for inhibiting growth of epithelial ovarian cancer as well as recombinant vector and application thereof |
| 06/12/2013 | CN103146702A Application of MiR-181a-5p in non-small cell lung cancer |
| 06/12/2013 | CN103146689A Short hairpin ribonucleic acid (shRNA) and shRNA application to preparation of medicines for curing colorectal cancer |
| 06/12/2013 | CN103146637A Method for preparation of flavone by culturing radix puerariae cells |